Beta Bionics (NASDAQ:BBNX) versus PolyPid (NASDAQ:PYPD) Head-To-Head Analysis

PolyPid (NASDAQ:PYPD) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for PolyPid and Beta Bionics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	0	0	3	1	3.25
Beta Bionics	0	3	5	1	2.78

PolyPid currently has a consensus target price of $11.33, suggesting a potential upside of 286.14%. Beta Bionics has a consensus target price of $24.83, suggesting a potential upside of 67.23%. Given PolyPid’s stronger consensus rating and higher possible upside, equities analysts clearly believe PolyPid is more favorable than Beta Bionics.

Insider and Institutional Ownership

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares PolyPid and Beta Bionics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$29.02 million	($4.97)	-0.59
Beta Bionics	$53.03 million	12.00	N/A	N/A	N/A

Beta Bionics has higher revenue and earnings than PolyPid.

Profitability

This table compares PolyPid and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-624.10%	-129.28%
Beta Bionics	N/A	N/A	N/A

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.